Adare Pharma Solutions

Adare Pharma Solutions, based in the US, specializes in contract development and manufacturing organization (CDMO) services, focusing on advanced oral dosage forms in the pharmaceutical industry. Founded in 1982 in Philadelphia, US, Adare Pharma Solutions provides CDMO services tailored for the pharmaceutical sector. The company, previously acquired by Frazier Healthcare Partners and Thomas H Lee Partners in September 2020, rebranded from Adare Pharmaceuticals, Inc. to Adare Pharma Solutions.

Under the leadership of CEO Tom Sellig, Adare has engaged in 7 notable deals, with the most recent funding round being a Trade Sale amounting to USD 2,900. 00 mn, which has raised a cumulative total of USD 2,900. 00 mn. Adare Pharma Solutions focuses on providing CDMO services for oral dosage forms within the pharmaceutical industry.

Their core offerings include advanced technologies for taste masking, controlled release, and solubility enhancement, alongside patient-centric dosing solutions. Innovations such as Advatab® for rapid disintegration and Diffutab® for targeted drug delivery exemplify their product range. Adare collaborates with pharmaceutical companies in over 100 countries, supporting more than 65 developed products across North America, Europe, and Asia. In the most recent fiscal year of 2011, Adare Pharma Solutions recorded a revenue of USD 470.

38 mn and an EBITDA of USD 6. 43 mn. Revenue generation is primarily achieved through B2B partnerships and direct sales, incorporating contract agreements for the development and manufacturing of oral dosage products. Following the September 2020 acquisition, Adare Pharma Solutions aims to leverage the new investment to enhance its pharmaceutical development and manufacturing capabilities.

The company is focused on launching new products and expanding its market presence, although specific upcoming products or regional markets targeted for expansion have not been disclosed. The recent funding will facilitate these strategic initiatives.